- Home
- NIVF vs CDT Comparison
NIVF vs CDT Comparison
Compare NIVF & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIVF
- CDT
- Stock Information
- Founded
- NIVF 2011
- CDT 2019
- Country
- NIVF Thailand
- CDT United States
- Employees
- NIVF N/A
- CDT N/A
- Industry
- NIVF
- CDT Biotechnology: Pharmaceutical Preparations
- Sector
- NIVF
- CDT Health Care
- Exchange
- NIVF NYSE
- CDT Nasdaq
- Market Cap
- NIVF 2.1M
- CDT 2.2M
- IPO Year
- NIVF N/A
- CDT N/A
- Fundamental
- Price
- NIVF $1.05
- CDT $2.74
- Analyst Decision
- NIVF
- CDT
- Analyst Count
- NIVF 0
- CDT 0
- Target Price
- NIVF N/A
- CDT N/A
- AVG Volume (30 Days)
- NIVF 9.1M
- CDT 725.7K
- Earning Date
- NIVF 01-01-0001
- CDT 08-11-2025
- Dividend Yield
- NIVF N/A
- CDT N/A
- EPS Growth
- NIVF N/A
- CDT N/A
- EPS
- NIVF N/A
- CDT N/A
- Revenue
- NIVF $5,433,375.00
- CDT N/A
- Revenue This Year
- NIVF N/A
- CDT N/A
- Revenue Next Year
- NIVF N/A
- CDT N/A
- P/E Ratio
- NIVF N/A
- CDT N/A
- Revenue Growth
- NIVF 5.79
- CDT N/A
- 52 Week Low
- NIVF $1.00
- CDT $2.21
- 52 Week High
- NIVF $656.00
- CDT $1,844.85
- Technical
- Relative Strength Index (RSI)
- NIVF 33.99
- CDT 31.11
- Support Level
- NIVF $1.00
- CDT $2.21
- Resistance Level
- NIVF $6.13
- CDT $2.58
- Average True Range (ATR)
- NIVF 0.17
- CDT 0.19
- MACD
- NIVF -0.01
- CDT 0.23
- Stochastic Oscillator
- NIVF 9.35
- CDT 54.45
About NIVF NEWGENIVF GROUP LIMITED
NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.
About CDT Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.